Carrier Screening and Diagnosis for Spinal Muscular Atrophy Using Droplet Digital PCR Versus MLPA: Analytical...

Area of Science:

• Genetics
• Molecular Biology
• Neurology

Background:

• Spinal muscular atrophy (SMA) is a severe genetic disorder.
• Population-wide screening for SMA carriers is recommended.
• Accurate and cost-effective methods are needed for SMA screening.

Purpose of the Study:

• To validate droplet digital PCR (ddPCR) for quantifying SMN1 and SMN2 copy number variations (CNVs).
• To compare ddPCR with Multiplex Ligation-dependent Probe Amplification (MLPA) for diagnostic accuracy.
• To assess the utility of ddPCR for SMA carrier screening and diagnosis.

Main Methods:

• Validated ddPCR for SMN1 and SMN2 exon 7 CNV determination.
• Tested 66 clinical samples using ddPCR.
• Compared ddPCR results with MLPA as the gold standard.

Main Results:

• ddPCR showed perfect concordance (κ = 1.000) with MLPA for SMN1 and SMN2 exon 7 CNVs.
• ddPCR demonstrated excellent repeatability (coefficient of variation < 4%).
• ddPCR is a cost-effective and time-saving alternative to MLPA.

Conclusions:

• ddPCR is a reliable method for CNV detection in SMA diagnosis and carrier screening.
• ddPCR results for SMN1/SMN2 exon 7 CNVs are concordant with the gold standard.
• ddPCR offers a more efficient and economical approach for SMA screening compared to MLPA.